Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Decibel Therapeutics

regeneron headquarters

Regeneron’s antibody cocktail REGEN-COV offers sustained protection against COVID-19

The drug is shown to give sustained protection against COVID-19, cutting the risk of infection by more than 80% for up to eight months

regeneron headquarters

FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19

In Europe, the EMA will review a Marketing Authorisation Application for the antibody cocktail

Disrupting Cell Engineering with Non-Viral Modalities

Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...

Impetus Digital

regeneron headquarters

US orders 1.4 million more doses of Regeneron antibody cocktail

The new $2.9bn order increases the amount of Regeneron’s anti-COVID REGEN-COV purchased by the US government to nearly 3 million doses

- PMLiVE

AbbVie signs gene therapy deal in eye care

AbbVie and REGENXBIO have teamed up on RGX-314, a potential one-time gene therapy against two leading causes of blindness, wet AMD and diabetic retinopathy.

- PMLiVE

US demand for COVID-19 antibody treatments rising fast

With the ‘fourth wave’ of COVID-19 in the US, Regeneron and GSK report high demand for their monoclonal antibody treatments

regeneron headquarters

UK approves Regeneron’s COVID-19 antibody cocktail

Ronapreve is the first monoclonal antibody therapy against COVID-19 approved in Europe

Realizing the Potential of Genomics-Driven Precision Medicine

Jennifer Helfer, Senior Director, Patient Advocacy & Engagement at Encoded Therapeutics Inc., discusses genomics-driven precision medicine, gene therapy misconceptions and fears, involving patients and caregivers in designing gene therapy trials,...

Impetus Digital

- PMLiVE

Researchers publish promising results for ultra-rare disease gene therapy method

Gene therapy method evaluated in seven children with aromatic amino acid decarboxylase deficiency

- PMLiVE

bluebird bio lodges counterclaim against Spark Therapeutics

Spark previously accused bluebird of misusing trademarks relating to the word ‘spark’ in marketing/educational materials

- PMLiVE

New data shows benefits for presymptomatic SMA patients treated with Zolgensma

Zolgensma was initially approved in 2019 for the treatment of SMA, launching with a list price of $2.125m

- PMLiVE

Regeneron’s COVID-19 drug boosts survival in hospitalised patients lacking antibodies

REGEN-COV reduced the risk of death among patients who did not have a natural antibody response

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links